reference/20972870

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20972870

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	86
issn	0920-1211
pageRange	80-86
publicationName	Epilepsy Research
startingPage	80
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c0b596698ff2b7af6d83772b096a53ac http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_530066bb453be14f9fca416bad609aef http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_3169a0437f30f88aa29054f308e4e01b http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_15526edec5a68f2bde936fd3d7357ca6 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a0c77b1373e914b0a28e8883bf3ec4d1
bibliographicCitation	Abou-Khalil B, Klein P, Shah A, Ryvlin P, Specchio LM, Gama H, Rocha F, Blum D, Grinnell T, Cheng H, Jung J. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures. Epilepsy Res. 2018 Nov;147():80–6. doi: 10.1016/j.eplepsyres.2018.08.011. PMID: 30278294.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_22ef096c92a8268ee0104fdd6a336901 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cbb96c44013ece48b1ae3cd4a2d260e0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e7c22cd367fd0df9af91737e0ddc1e57 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d5d13b3d2fdfbed6e6981763878a2ad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4af7bea9f6dbb005ec08006079bfbdfa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16937b02f0361bc66a1c99ea719f248a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3de083ce87646b6b86690bac7ca147ba http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7370-3004 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ce4ff55fcc11e539dc33465564bcaba http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7775-6576 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_61c473ccf187978762f987b89ad03996 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0bd53662228bca0eb4838701569199c8
date	201811
identifier	https://pubmed.ncbi.nlm.nih.gov/30278294 https://doi.org/10.1016/j.eplepsyres.2018.08.011
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3587 https://portal.issn.org/resource/ISSN/0920-1211
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures
discusses	http://id.nlm.nih.gov/mesh/M0003328 http://id.nlm.nih.gov/mesh/M0001382 http://id.nlm.nih.gov/mesh/M0137818 http://id.nlm.nih.gov/mesh/M0006249 http://id.nlm.nih.gov/mesh/M0374531
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D012640Q000188 http://id.nlm.nih.gov/mesh/D000927Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000077213Q000627 http://id.nlm.nih.gov/mesh/D002220Q000627 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D016032 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D014839Q000139 http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D005500 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D003984Q000627 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D004172Q000139 http://id.nlm.nih.gov/mesh/D002648 http://id.nlm.nih.gov/mesh/D005260
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID179344 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9594 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7907 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2554 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7483 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3878 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7469 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9191 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1775 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614

Total number of triples: 67.